GlobeNewswire

Canada's CoinField cryptocurrency exchange going international with commission-free trading app moonGO through a new partnership

Dela

moonGO(TM) app is the fastest and most reliable way to buy/sell and store cryptocurrencies. The app allows users to convert cryptos directly to EUR/USD to be loaded into their moonGo(TM) card and be used anywhere worldwide whether they're shopping online or spending it at a physical retailer who accepts credit cards.

VANCOUVER, British Columbia, July  23, 2018  (GLOBE NEWSWIRE) -- CoinField, the most advanced cryptocurrency exchange in Canada is now extending its services worldwide thanks to a new partnership with Malta's Manticore Ventures to create moonGO(TM), a powerful app designed for traders who thrive on agility, flexibility and security.

With moonGO(TM), users can set up their trading accounts in about 60 seconds, withdraw fiat currency as Euro or US dollars in the form of moonGO(TM) cards, and use the moonGO(TM) cards to make purchases online or at any retailer that accepts credit cards. The moonGO(TM) app will take CoinField's sterling reputation outside of Canada and make its services available to every country in the world except the US and the nations on the US/UN sanction list (Iran, Syria, Sudan, Cuba, North Korea, Burma, Côte d'Ivoire).

"Our vision is to bring the cryptocurrency to people's lives in the most convenient and simple way, and make it available to well-qualified traders in most countries worldwide," CoinField CEO Babak Bob Ras said. "While the users benefit from commission-free trading, they can also convert their assets to fiat at anytime and spend it anywhere in the world through our moonGO(TM) cards. Everyone deserves to have access to blockchain technology. There are many people who want to be part of this revolution, but until now it was not easy for them to enter."

The app offers commission-free buy/sell transactions for popular cryptocurrencies including: Bitcoin, Ethereum, Ripple, Dash, Litecoin, Bitcoin Cash, Bitcoin Gold, Select ERC20 coins & non-ERC20.

But moonGO(TM) goes beyond the exchange of cryptocurrencies. It allows users to withdraw their funds in Euros or US dollars using moonGO(TM) virtual cards. These cards can be added to their Apple Pay, Google Pay, or Samsung Pay accounts. Users can also withdraw their digital assets to their wallets outside the platform at any time.

Just as impressive is the app's reduction of the verification and Know Your Customer (KYC) process from 4-6 weeks to mere seconds thanks to CoinField's multi-algorithm solution. While the approval time may have dropped, the commitment to our Anti-money Laundering policy is as vigilant as ever.  moonGO(TM) employs a very strict AML/KYC policy to fight money laundering activities. Company executives toe a strong line on corruption in cryptocurrency, stating: "Any and all attempts to hurt our traders and tarnish the perception of the revolutionary blockchain technology will be met with the full force of our cutting-edge security infrastructure."

moonGO(TM) will enforce that statement by actively and voluntarily filing reports with regulatory and enforcement agencies that ensure a safe, legal, and secure trading experience for all users.

Among moonGO(TM)'s additional layers of security is the new Secret Vault technology: a virtual "safe" storing sensitive information behind a virtual cloud with a hidden location. The app also features Multi-Signature Wallets that require signatures from multiple peers to ensure legitimacy; DDoS Protection by Cloudflare; Isolated Server Access; and Suspicious Activity Logger. All of these components unite to create a hack-proof trading ecosystem.

Timeline

  • Currently in Phase One, moonGO(TM) is available only to users who register their email addresses for an "Early Access Invite". Early access registration is currently open at https://www.moongo.com
  • moonGO(TM) will launch its alpha version in Q4 2018 with a maximum of 250,000 users from the aforementioned Phase One email registration.
  • The moonGO(TM) app will be available to the public in Q1 2019.
  • CoinField and Manticore hope to bring moonGO(TM) to the US market during fiscal year 2019.

CoinField is Canada's most advanced trading platform, owned and operated by Central Crypto Exchange Corp in Vancouver, Canada. More information can be found at https://www.coinfield.com. moonGO(TM) is 100% owned by Malta's Manticore Ventures Ltd. Manticore is a VC group focused on Fintech and Blockchain technology projects. More information about moonGO(TM) app can be found at https://www.moongo.com.

Contact:
Company: Central Crypto Exchange Corp.  Manticore Ventures Ltd.
E-mail: press@coinfield.com
https://www.coinfield.com
https://www.moongo.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CoinField via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum